Influence of the interval between transcatheter arterial embolization and radiofrequency ablation on the treatment outcome of small hepatocellular carcinoma

Yu SUN; Honghai ZHANG; Jiang LONG; Shoupeng SHENG; Jiasheng ZHENG; Yonghong ZHANG

doi:10.3969/j.issn.1001-5256.2022.10.016

Volume 38 Issue 10

Oct. 2022

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2022 > 38(10): 2286-2289

PDF( 1758 KB)

Influence of the interval between transcatheter arterial embolization and radiofrequency ablation on the treatment outcome of small hepatocellular carcinoma

DOI: 10.3969/j.issn.1001-5256.2022.10.016

Center of Interventional Oncology and Liver Diseases, Beijing YouAn Hospital, Capital Medical University, Beijing 100069, China

Research funding:

Scientific Research and Cultivation Plan of Beijing Municipal Hospitals (PX2022067);

Natural Science Foundation of Beijing Municipality (7191004);

Beijing Key Laboratory of Biomarkers for Infectious Diseases (BZ0373)

More Information

Corresponding author: ZHANG Yonghong, 13810108505@163.com(ORCID: 0000-0002-1357-7891)
Received Date: 2022-03-02
Accepted Date: 2022-04-05
Published Date: 2022-10-20

Abstract

Abstract

Objective To investigate the influence of the interval between transcatheter arterial embolization (TAE) and radiofrequency ablation on the treatment outcome of small hepatocellular carcinoma. Methods A total of 70 patients with hepatocellular carcinoma who received treatment in Beijing YouAn Hospital, Capital Medical University, from January 2019 to June 2020 were enrolled and divided into observation group (radiofrequency ablation was performed on the day or the second day of TAE) and control group (radiofrequency ablation was performed at 1-2 weeks after TAE) using a random number table, with 35 patients in each group. The independent samples t-test was used for comparison of continuous data between two groups, and the paired t-test was used for comparison of observation indicators before and after surgery; the chi-square test was used for comparison of categorical data between two groups. Results The observation group had a significantly shorter length of hospital stay than the control group (7.80±2.76 days vs 14.31±2.19 days, t=-10.93, P < 0.001). There were no significant differences between the observation group and the control group in complete ablation rate (95.12% vs 95.00%, χ²=0.001, P=0.980), incidence rate of adverse reactions (25.71% vs 20.00%, χ²=0.324, P=0.569), and 1-year recurrence rate (11.43% vs 14.29%, χ²=0.128, P=0.721), and there were also no significant differences in laboratory markers between the two groups before and after treatment (all P > 0.05). Conclusion TAE combined with sequential radiofrequency ablation at a short interval is safe and effective in the treatment of small hepatocellular carcinoma and can significantly shorten the length of hospital stay and reduce hospital costs, and therefore, it holds promise for clinical application.
- Carcinoma, Hepatocellular,
- Embolization, Therapeutic,
- Local Ablation,
- Treatment Outcome

FullText(HTML)

References(14)

References

[1]	BRAY F, FERLAY J, SOERJOMATARAM I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6): 394-424. DOI: 10.3322/caac.21492.
[2]	ZHOU R, LI S, WAN WJ, et al. Comparison of clinical prognosis between surgical resection and local thermal ablation for small liver cancer[J/CD]. Chin J Hepat Surg (Electronic Edition), 2021, 10(3): 258-262. DOI: 10.3877/cma.j.issn.2095-3232.2021.03.006. 周瑞, 李珊, 万文军, 等. 手术切除与局部热消融治疗小肝癌预后比较[J/CD]. 中华肝脏外科手术学电子杂志, 2021, 10(3): 258-262. DOI: 10.3877/cma.j.issn.2095-3232.2021.03.006.
[3]	LIU YY, LAI JX. Minimally invasive interventional therapy for liver cancer[J/CD]. Chin J Hepat Surg: Electronic Edition, 2020, 9(3): 201-205. DOI: 10.3877/cma.j.issn.2095-3232.2020.03.001. 刘允怡, 赖俊雄. 肝癌微创介入治疗[J/CD]. 中华肝脏外科手术学电子杂志, 2020, 9(3): 201-205. DOI: 10.3877/cma.j.issn.2095-3232.2020.03.001.
[4]	KIM JW, KIM JH, WON HJ, et al. Hepatocellular carcinomas 2-3 cm in diameter: transarterial chemoembolization plus radiofrequency ablation vs. radiofrequency ablation alone[J]. Eur J Radiol, 2012, 81(3): e189-e193. DOI: 10.1016/j.ejrad.2011.01.122.
[5]	XIONG K, BAI F, CHEN DN, et al. Comparison of the effcacy and safety of the combined treatment of transcatheter arterial chemoembolization and radiofrequency ablation with transcatheter arterial chemoembolization or radiofrequency ablation treatment alone in patients with primary hepatic carcinoma in China[J]. Chin Health Resources, 2018, 21(3): 271-274, 279. DOI: 10.13688/j.cnki.chr.2018.17765. 熊琨, 白飞, 陈丹妮, 等. 中国原发性肝癌肝动脉化疗栓塞术和射频消融联合治疗与单独治疗的有效性和安全性比较[J]. 中国卫生资源, 2018, 21(3): 271-274, 279. DOI: 10.13688/j.cnki.chr.2018.17765.
[6]	ZHANG M, HUANG J, XIAO HX, et al. Time node study of sequential treatment of primary hepatocellular carcinoma by hepatic artery embolization chemotherapy combined with microwave ablation guided by ultrasound[J]. J Clin Exp Med, 2021, 20(10): 1080-1083. DOI: 10.3969/j.issn.1671-4695.2021.10.020. 张明, 黄君, 肖华旭, 等. 肝动脉栓塞化疗联合超声引导下微波消融序贯治疗原发性肝癌的时间节点研究[J]. 临床和实验医学杂志, 2021, 20(10): 1080-1083. DOI: 10.3969/j.issn.1671-4695.2021.10.020.
[7]	National Health and Family Planning Commission of the People's Republic of China. Diagnosis, management, and treatment of hepatocellular carcinoma (V2017)[J]. J Clin Hepatol, 2017, 33(8): 1419-1431. DOI: 10.3969/j.issn.1001-5256.2017.08.003. 中华人民共和国国家卫生和计划生育委员会. 原发性肝癌诊疗规范(2017年版)[J]. 临床肝胆病杂志, 2017, 33(8): 1419-1431. DOI: 10.3969/j.issn.1001-5256.2017.08.003.
[8]	CAI DS, ZHU WD, LI Z. Superselective hepatic arterial embolization associated with radiofrequency ablation in treating primary small hepatocellular carcinoma[J]. J Intervent Radiol, 2008, 17(3): 218-219. DOI: 10.3969/j.issn.1008-794X.2008.03.020. 蔡东顺, 朱望东, 李哲. 超选择性肝动脉栓塞与射频消融术联合治疗小肝癌[J]. 介入放射学杂志, 2008, 17(3): 218-219. DOI: 10.3969/j.issn.1008-794X.2008.03.020.
[9]	WANG Y, MA L, SHENG S, et al. Combination therapy of TACE and CT-guided partial hepatic segment ablation for liver cancer[J]. Minim Invasive Ther Allied Technol, 2018, 27(6): 355-364. DOI: 10.1080/13645706.2018.1462833.
[10]	OH JH, SINN DH, CHOI GS, et al. Comparison of outcome between liver resection, radiofrequency ablation, and transarterial therapy for multiple small hepatocellular carcinoma within the Milan criteria[J]. Ann Surg Treat Res, 2020, 99(4): 238-246. DOI: 10.4174/astr.2020.99.4.238.
[11]	SI ZM, WANG GZ, QIAN S, et al. Combination therapies in the management of large (≥5 cm) hepatocellular carcinoma: Microwave ablation immediately followed by transarterial chemoembolization[J]. J Vasc Interv Radiol, 2016, 27(10): 1577-1583. DOI: 10.1016/j.jvir.2016.02.014.
[12]	JIN H, WANG H, LI G, et al. Risk factors for early postoperative recurrence in single and small hepatitis B virus-associated primary hepatocellular carcinoma[J]. J Int Med Res, 2020, 48(10): 300060520961260. DOI: 10.1177/0300060520961260.
[13]	GUO WP, WANG J, GUAN YW, et al. TACE combined with microwave ablation versus radical surgical resection for the treatment of small HCC: a comparison study[J]. J Intervent Radiol, 2019, 28(7): 642-646. DOI: 10.3969/j.issn.1008-794X.2019.07.007. 郭玮平, 王杰, 管一伟, 等. 肝动脉化疗栓塞联合微波消融与外科根治性切除治疗小肝癌的对照研究[J]. 介入放射学杂志, 2019, 28(7): 642-646. DOI: 10.3969/j.issn.1008-794X.2019.07.007.
[14]	LI Z, HAO D, JIAO D, et al. Transcatheter arterial chemoembolization combined with simultaneous cone-beam computed tomography-guided microwave ablation in the treatment of small hepatocellular carcinoma: Clinical experiences from 50 procedures[J]. Acad Radiol, 2021, 28(Suppl 1): s64-s70. DOI: 10.1016/j.acra.2020.08.036.

Relative Articles

[1]	Zexin HU, Jiaqing LI, Wanci LI, Binyan ZHONG, Shuai ZHANG, Jian SHEN, Xiaoli ZHU. Efficacy and safety of transcatheter arterial chemoembolization combined with targeted therapy and immunotherapy in treatment of patients with stage Ⅱ‍b/Ⅲ‍a hepatocellular carcinoma based on China Liver Cancer Staging[J]. Journal of Clinical Hepatology, 2024, 40(3): 550-555. doi: 10.12449/JCH240318
[2]	Qiuju PENG, Tao DAI, Guibo XIE, Jinjun CHEN, Xiao CHENG, Yuan YAN. Research advances in transcatheter arterial chemoembolization combined with targeted agents or anti-PD-1/PD-L1 monoclonal antibody in treatment of patients with unresectable hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2023, 39(7): 1740-1746. doi: 10.3969/j.issn.1001-5256.2023.07.033
[3]	Bailu CAO, Min AI, Ping HUANG, Yongfeng YANG. Research advances in local treatment combined with systemic therapy for advanced hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2023, 39(8): 1972-1976. doi: 10.3969/j.issn.1001-5256.2023.08.031
[4]	Jing LUO, Caihong LYU, Yongping YANG. Clinical efficacy and safety of percutaneous cryoablation combined with percutaneous ethanol injection in elderly patients with hepatocellular carcinoma aged 70 years or older[J]. Journal of Clinical Hepatology, 2022, 38(2): 365-371. doi: 10.3969/j.issn.1001-5256.2022.02.021
[5]	Jun LING, Wenwu WAN, Zheng ZENG, Huihua YAO, Ou JIANG, Bing DING. Clinical effect of transcatheter arterial chemoembolization combined with microwave ablation versus repeat resection in treatment of recurrent hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2022, 38(9): 2053-2060. doi: 10.3969/j.issn.1001-5256.2022.09.020
[6]	Yihan YANG, Wanci LI, Binyan ZHONG, Jian SHEN, Xiaoli ZHU. Efficacy and safety of transarterial chemoembolization combined with camrelizumab and apatinib in treatment of advanced hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2022, 38(12): 2755-2760. doi: 10.3969/j.issn.1001-5256.2022.12.014
[7]	Xiaomin LIU, Wei SUN, Jianying WEI, Wendong LI, Xiaoyan DING, Minghua YU, Jinglong CHEN. Efficacy and safety of lenvatinib in patients with unresectable hepatocellular carcinoma previously treated with tyrosine kinase inhibitor[J]. Journal of Clinical Hepatology, 2022, 38(6): 1323-1327. doi: 10.3969/j.issn.1001-5256.2022.06.020
[8]	Xiaopeng DING, Jun TIE, Jiahao YU, Pengwei REN, Guoyun XUAN, Shuoyi MA, Changcun GUO, Ying HAN, Xinmin ZHOU. Efficacy and safety of programmed death-1 inhibitor combined with transarterial chemoembolization and anti-angiogenic drugs in treatment of advanced hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2022, 38(5): 1086-1091. doi: 10.3969/j.issn.1001-5256.2022.05.021
[9]	Chunxia PING, Jing ZHANG, Wei ZHAO, Liang MA, Da FANG, Shichang CUI. Three-year follow-up outcomes of hepatocellular carcinoma patients undergoing liver resection versus liver transplantation[J]. Journal of Clinical Hepatology, 2021, 37(2): 343-347. doi: 10.3969/j.issn.1001-5256.2021.02.019
[10]	Yanmei ZOU, Xianglin YUAN. Application value of immunotherapy in hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2021, 37(8): 1758-1760. doi: 10.3969/j.issn.1001-5256.2021.08.004
[11]	Ningning ZHANG, Wei LU. Targeted therapy for hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2021, 37(8): 1753-1757. doi: 10.3969/j.issn.1001-5256.2021.08.003
[12]	Zhiyuan YU, Shiyu YANG, Jiaqi LI, Yan SUN. Current developmental status of non-surgical treatment of hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2021, 37(5): 1205-1207. doi: 10.3969/j.issn.1001-5256.2021.05.048
[13]	Yisheng PENG, Pan HE, Gang ZHU, Xinkai LI, Shunde TAN, Jianfei CHEN, Jun FAN, Bin LUO, Song SU, Bo LI, Xiaoli YANG. Efficacy and safety of CalliSpheres microsphere versus conventional transcatheter arterial chemoembolization in treatment of hepatocellular carcinoma: A Meta-analysis[J]. Journal of Clinical Hepatology, 2021, 37(8): 1841-1847. doi: 10.3969/j.issn.1001-5256.2021.08.019
[14]	Lu Jian, Zhu HaiDong, Teng GaoJun, Wang Zhi. Role of interventional therapy in the downstaging of advanced liver cancer[J]. Journal of Clinical Hepatology, 2020, 36(2): 272-276. doi: 10.3969/j.issn.1001-5256.2020.02.006
[15]	Tang JinQuan, He Pan, Su Song, Luo Bin, Fang Cheng, Li Bo, Xia XianMing, Li YuWei. Short-and long-term effects of radiofrequency ablation versus minimally invasive hepatectomy in treatment of small hepatocellular carcinoma: A Meta-analysis[J]. Journal of Clinical Hepatology, 2020, 36(2): 358-362. doi: 10.3969/j.issn.1001-5256.2020.02.025
[16]	Xing AiLi, Zheng JiaSheng. Clinical effect of transcatheter arterial chemoembolization combined with local thermal ablation in treatment of large hepatocellular carcinoma and related influencing factors[J]. Journal of Clinical Hepatology, 2019, 35(1): 98-103. doi: 10.3969/j.issn.1001-5256.2019.01.018
[17]	Liang HongYuan, Guo QiYong, Mao XiaoNan, Sun Wei, Zhao Gang, Wang XiHai, Liu Zhen, Wen Feng, Lu ZaiMing. Clinical effect of sequential therapy with transarterial chemoembolization and bipolar-needle radiofrequency ablation in treatment of hepatocellular carcinoma in high-risk locations[J]. Journal of Clinical Hepatology, 2018, 34(7): 1462-1469. doi: 10.3969/j.issn.1001-5256.2018.07.020
[18]	Wang HuaMing. The interventional treatment for hepatocellular carcinoma originating from the caudate lobe[J]. Journal of Clinical Hepatology, 2016, 32(1): 68-71. doi: 10.3969/j.issn.1001-5256.2016.01.010
[19]	Sun Wei, Ding XiaoYan, Chen JingLong. Clinical effect and safety of percutaneous radiofrequency ablation following transcatheter arterial chemoembolization in treatment of primary liver cancer in high-risk locations[J]. Journal of Clinical Hepatology, 2016, 32(12): 2337-2341. doi: 10.3969/j.issn.1001-5256.2016.12.021
[20]	Zhu XiaoLi, Shen Jian. Application of local ablative therapies for hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2016, 32(1): 56-61. doi: 10.3969/j.issn.1001-5256.2016.01.008

Supplements(0)

Cited By

Cited by

Periodical cited type(3)

1.	周亚丹. 围术期预见性护理对肝癌射频消融术患者的影响. 国际医药卫生导报. 2023(05): 708-713 .
2.	程镉镉，彭沙沙. 肝细胞癌自发性破裂出血相关危险因素及治疗进展. 国际外科学杂志. 2023(08): 562-566 .
3.	姚加堤. 射频消融术在原发性肝癌术后复发患者中的应用价值. 中外医学研究. 2023(29): 49-52 .

Other cited types(2)

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Tables(2)

Get Citation

PDF

XML

Article Metrics

Article views (467) PDF downloads(38)

Influence of the interval between transcatheter arterial embolization and radiofrequency ablation on the treatment outcome of small hepatocellular carcinoma

DOI: 10.3969/j.issn.1001-5256.2022.10.016